Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Autoimmune Encephalopathies
The Neurologist 13:140-147, Vernino, S.,et al, 2007
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Ventilatory Failure in Myasthenia Gravis
JNNP 45:217-222, Ferguson,I.T.,et al, 1982